

## TME PHARMA ANNOUNCES COMPLETION OF SHARE CONSOLIDATION

**Berlin, Germany, July 27, 2022, 07:00 p.m. CEST – TME Pharma N.V., (Euronext Growth Paris: ALTME),** a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the amendment of the Articles of Association effecting the share consolidation such that every 100 shares with a nominal value of 1 eurocent each were consolidated and converted into 1 new share with a nominal value of 1 euro.

With the publication of this press release, i.e., after the share consolidation has taken effect, the total issued share capital amounts to €1,361,094 divided into 1,361,094 shares of € 1.00 each. Trading of the new shares with ISIN NL0015000YE1 on the Euronext Growth Paris market will commence on July 28, 2022, and reverse stock split settlement will take place on August 1, 2022.

The table below summarizes key remaining process steps and dates in the share consolidation process.

Description	Date
Last trading day of the old shares	July 27, 2022
End of the 30-day parity period	July 27, 2022
Ex-Date, first trading day of the new shares	July 28, 2022
Last day of settlement of exercised option and conversion rights into old shares	July 28, 2022
Record date	July 29, 2022
Last day of the suspension period	July 29, 2022
Settlement of the reverse stock split and first day of settlement of exercised option and conversion rights into new shares	August 1, 2022
Payment proceeds of aggregated whole shares to holders of fractional entitlements	Expected before the beginning of September but subject to the market conditions and measures being followed by relevant brokers to maintain an orderly market.

**For more information, please contact:**

**TME Pharma N.V.**

Aram Mangasarian, Ph.D., CEO

Bryan Jennings, CFO

Tel. +49 (0) 30 726247 0

investors@tmepharma.com

**Investor and Media Relations:**

**LifeSci Advisors**

Guillaume van Renterghem

Tel. +41 (0) 76 735 01 31

gvanrenterghem@lifesciadvisors.com

**NewCap**

Arthur Rouillé

Tel. +33 (0) 1 44 71 00 15

arouille@newcap.fr

**About TME Pharma**

*TME Pharma* is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, *TME Pharma's* approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA clinical trial, *TME Pharma* is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. *TME Pharma* has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses. NOX-A12 in combination with radiotherapy has received orphan drug designation for glioblastoma in the United States and glioma in Europe. *TME Pharma* has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial is in discussion with regulatory authorities in the United States and Europe. The company's second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. *TME Pharma* is considering several solid tumors for further clinical development. Further information can be found at: [www.tmepharma.com](http://www.tmepharma.com).

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Visit *TME Pharma* on [LinkedIn](#) and [Twitter](#).

### **About the GLORIA Study**

GLORIA (NCT04121455) is *TME Pharma's* dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab.

### **About the OPTIMUS Study**

OPTIMUS (NCT04901741) is *TME Pharma's* planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

### **Disclaimer**

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on *TME Pharma's* current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and *TME Pharma's* ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and *TME Pharma* undertakes no duty to update such information except as required under applicable law.